FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100048938> ?p ?o ?g. }

• W2100048938 endingPage "806" @default.
• W2100048938 startingPage "797" @default.
• W2100048938 abstract "In a previous report we have characterized cisplatin (CDDP)-resistant sublines (HLac 79-DDP1 to DDP4) of the recloned squamous cell head and neck cancer (SCHNC) line HLac 79-ML revealing significant alterations of glutathione (GSH) metabolism and drug accumulation. in order to overcome CDDP-resistance in HLac 79 cells we now investigated the effect of buthionine sulfoximine (BSO), a specific inhibitor of GSH synthesis, verapamil (VRP), a calcium channel blocker that has been found to modulate resistance towards a broad spectrum of antineoplastic drugs, cyclosporin a (CSA), an immunosuppressive agent probably affecting drug pharmacokinetics, and aphidicolin (APC), a fungal metabolite interfering with DNA repair through inhibition of DNA polymerase alpha, on HLac 79 CDDP-sensitivity. Using the colorimetric MTT assay, GSH depletion with BSO led to a significant decrease of the 50 % inhibitory drug concentration (IC50) in all HLac 79 sublines by dose modifying factors (IC50, CDDP/IC50 BSO + CDDP) ranging from 1.8 to 3.3. VRP, CSA or APC were not effective to overcome CDDP resistance in HLac 79 cells. the potential of BSO to modulate CDDP resistance in vitro was tested in vivo in HLac 79 tumor bearing NMRI nu-nu mice subsequently. Oral administration of BSO 7 days prior and during (days -7 to 8) CDDP treatment (3 mg/kg bw i.p. days 0, 4, 8) produced a significant prolongation of mean survival time x as compared to chemotherapy alone. This held true for both the maternal line ML in terms of chemosensitization (CDDP: x=40.2 ± 15.9 days vs. CDDP+BSO: x=80.3 ± 30.4 days, p<0.001) and the CDDP resistant subline DDP4 in terms of partially overcoming secondary drug resistance (CDDP: x=56.5 ± 13.6 days vs. CDDP+BSO: x=72.5 ± 15.8 days, p<0.001). Enhanced toxicity of combined BSO and CDDP treatment manifested by transient 10% reduction of animal mean body weight." @default.
• W2100048938 created "2016-06-24" @default.
• W2100048938 creator A5083143288 @default.
• W2100048938 date "1991-01-01" @default.
• W2100048938 modified "2023-09-23" @default.
• W2100048938 title "Circumvention of Drug Resistance in Cisplatin-resistant Sublines of the Human Squamous Carcinoma Cell Line HLac 79 in Vitro and in Vivo" @default.
• W2100048938 cites W154283310 @default.
• W2100048938 cites W1987649511 @default.
• W2100048938 cites W1997284704 @default.
• W2100048938 cites W1999805615 @default.
• W2100048938 cites W2018577228 @default.
• W2100048938 cites W2062381728 @default.
• W2100048938 cites W2080739892 @default.
• W2100048938 cites W2081159061 @default.
• W2100048938 cites W2091166505 @default.
• W2100048938 cites W2094188453 @default.
• W2100048938 cites W2096014395 @default.
• W2100048938 cites W2107705897 @default.
• W2100048938 cites W2114918609 @default.
• W2100048938 cites W2127407428 @default.
• W2100048938 cites W2505754584 @default.
• W2100048938 doi "https://doi.org/10.3109/00016489109138414" @default.
• W2100048938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1950544" @default.
• W2100048938 hasPublicationYear "1991" @default.
• W2100048938 type Work @default.
• W2100048938 sameAs 2100048938 @default.
• W2100048938 citedByCount "11" @default.
• W2100048938 crossrefType "journal-article" @default.
• W2100048938 hasAuthorship W2100048938A5083143288 @default.
• W2100048938 hasConcept C109316439 @default.
• W2100048938 hasConcept C181199279 @default.
• W2100048938 hasConcept C202751555 @default.
• W2100048938 hasConcept C207001950 @default.
• W2100048938 hasConcept C2776375370 @default.
• W2100048938 hasConcept C2776694085 @default.
• W2100048938 hasConcept C2777752497 @default.
• W2100048938 hasConcept C2778239845 @default.
• W2100048938 hasConcept C538909803 @default.
• W2100048938 hasConcept C54355233 @default.
• W2100048938 hasConcept C55493867 @default.
• W2100048938 hasConcept C81885089 @default.
• W2100048938 hasConcept C86803240 @default.
• W2100048938 hasConcept C98274493 @default.
• W2100048938 hasConceptScore W2100048938C109316439 @default.
• W2100048938 hasConceptScore W2100048938C181199279 @default.
• W2100048938 hasConceptScore W2100048938C202751555 @default.
• W2100048938 hasConceptScore W2100048938C207001950 @default.
• W2100048938 hasConceptScore W2100048938C2776375370 @default.
• W2100048938 hasConceptScore W2100048938C2776694085 @default.
• W2100048938 hasConceptScore W2100048938C2777752497 @default.
• W2100048938 hasConceptScore W2100048938C2778239845 @default.
• W2100048938 hasConceptScore W2100048938C538909803 @default.
• W2100048938 hasConceptScore W2100048938C54355233 @default.
• W2100048938 hasConceptScore W2100048938C55493867 @default.
• W2100048938 hasConceptScore W2100048938C81885089 @default.
• W2100048938 hasConceptScore W2100048938C86803240 @default.
• W2100048938 hasConceptScore W2100048938C98274493 @default.
• W2100048938 hasIssue "4" @default.
• W2100048938 hasLocation W21000489381 @default.
• W2100048938 hasLocation W21000489382 @default.
• W2100048938 hasOpenAccess W2100048938 @default.
• W2100048938 hasPrimaryLocation W21000489381 @default.
• W2100048938 hasRelatedWork W1994790143 @default.
• W2100048938 hasRelatedWork W2006425566 @default.
• W2100048938 hasRelatedWork W2052185098 @default.
• W2100048938 hasRelatedWork W2054359817 @default.
• W2100048938 hasRelatedWork W2059025601 @default.
• W2100048938 hasRelatedWork W2114534540 @default.
• W2100048938 hasRelatedWork W2391782128 @default.
• W2100048938 hasRelatedWork W2407812582 @default.
• W2100048938 hasRelatedWork W3165143150 @default.
• W2100048938 hasRelatedWork W2186276880 @default.
• W2100048938 hasVolume "111" @default.
• W2100048938 isParatext "false" @default.
• W2100048938 isRetracted "false" @default.
• W2100048938 magId "2100048938" @default.
• W2100048938 workType "article" @default.